Message #17 From:
NewsBot Date: January 17, 2007 11:00:00 AM
AIS News Antares Pharma Announces the Addition of Leonard S. Jacob, M.D., Ph.D. to the Board of Directors
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (Amex:AIS) has elected Leonard S. Jacob, M.D.,
Ph.D. to the Company’s Board of Directors.
Dr. Leonard Jacob joins Antares with over 29 years of pharmaceutical
industry experience including having founded InKine Pharmaceutical
Company Inc. in 1997 and served as Chairman and CEO from its founding
until the company was acquired by Salix Pharmaceuticals in 2005. In 1989
Dr. Jacob co-founded Maganin Pharmaceuticals and served as its COO until
1996. From 1980 to 1989 Dr. Jacob served in a variety of executive roles
including Worldwide Vice President of SmithKline & French Labs (now
Glaxo-SmithKline) and as a member of their Corporate Management
Committee. He earned a Ph.D. in pharmacology from Temple University and
an M.D. from the Medical College of Pennsylvania (Drexel University
College of Medicine). Dr. Jacob currently serves as Chairman of Life
Science Advisors, a consulting group to the healthcare industry and is
non-executive Chairman of the Board of Bradley Pharmaceuticals, Inc., a
specialty pharma company focused principally on niche physician
specialty markets in the U.S. He also serves on the Board of the Colon
Cancer Alliance and the Board of Overseers for Temple University School
of Medicine and is a founding Director of the Jacob Internet fund, a
public mutual fund.
Jack E. Stover, President & CEO of Antares, stated, “We
welcome Dr. Jacob to our Board of Directors and are pleased to be
working with such a seasoned executive. His level of expertise and
understanding of all aspects of our industry will be invaluable to
Antares as we move forward with execution of our business plan as a
specialty pharmaceutical company.”
Antares Pharma is a specialized pharma product development company
focused on developing patented drug delivery systems and injectable
device engineering capabilities. Antares’
current technology platforms include its ATD™
Advanced Transdermal Delivery system, and its related TecTix™
system for topical and transmucosal delivery, its Easy Tec™
oral fast-melt technology, and subcutaneous injection technology
platforms including both Vibex™ disposable
mini-needle injection device and Valeo™/Vision®
reusable needle-free injection devices. Antares Pharma is committed to
leveraging its multiple drug delivery platforms to add value to existing
drugs and to create new pharmaceutical products and injectable devices.
Overall, Antares’ product pipeline, if
approved, will address unmet medical needs by reducing side effect
profiles, improving safety, increasing effectiveness, and improving
patient compliance and convenience. Antares Pharma has corporate
headquarters in Princeton Crossroads Corporate Center in Ewing, NJ, with
subsidiaries performing research, development, manufacturing and product
commercialization activities in Minneapolis, Minnesota and Basel,
Switzerland.
